VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease

Trial Profile

VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Pharmacokinetics
  • Acronyms VEDO-PREDIRESP
  • Most Recent Events

    • 18 Jul 2018 Planned End Date changed from 1 Jul 2018 to 1 Jun 2020.
    • 18 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2019.
    • 21 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top